Clinical Validation Unani Pharmacopoeial Formulation â?? Habb-e-Banafsha in Zeeq un-Nafas Rewi (Bronchial Asthma)

Central Council for Research in Unani Medicine CCRUM New Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

研究概览

暂无简介。

•1. Subjects of either sex between the age group of 18-65 years.
•2. Subjects of Bronchial Asthma for at least 6 months presenting with at least one of the following symptoms:
•Shortness of breath
•Chest tightness and cough that vary over
•time and in intensity,
•Expiratory airflow limitation as suggested
•by a decreased FEV1
•3. Objective evidence for reversible airway
•obstruction (>=12% and >=200 mL change in FEV1
•and/or a 25% and 60 L/min change in PEFR)
•either spontaneously or after treatment.
•4. Subjects with Asthma Control Questionnaire Score > 1.5

•1. FEV1/FVC ratio < 50%
•2. Pregnant and lactating females
•3. Subjects with other Respiratory Tract Infections, tuberculosis and malignancy.
•4. Subjects of Presence of chronic cough with expectoration for 2-3 months in each of two successive years.
•5. Subjects with co-morbidities; Diabetes Mellitus, Hepatic and Renal Insufficiency
•6. Subjects with known interstitial lung disease.
•7. Subjects with Tobacco Smoking.
•8. Subjects with known chronic obstructive pulmonary disease (COPD)
•9. Patient with regular use of oral or systemic corticosteroids for conditions other than Asthma.
•10. Subjects who are not willing to participate in the study.

发起方

Central Council for Research in Unani Medicine CCRUM New Delhi